Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re: Verinata Health, Inc.
Case Number:
17-109
Court:
Nature of Suit:
Companies
Sectors & Industries:
-
March 09, 2017
Fed. Circ. Won't Look At Reach Of AIA Estoppel Provision
The Federal Circuit on Thursday declined to address whether courts are misapplying the inter partes review estoppel provision and allowing those challenging patents to raise too many invalidity arguments, telling Illumina Inc. it can bring up the issue later on.
-
February 15, 2017
Ariosa Urges Fed. Circ. Not To Review AIA Estoppel Provision
Ariosa urged the Federal Circuit Tuesday to deny Illumina's mandamus petition arguing that courts are applying the America Invents Act's estoppel provision too narrowly and allowing inter partes review petitioners to make too many arguments in district court after a Patent Trial and Appeal Board decision, saying mandamus isn't warranted.
-
February 10, 2017
BIO, PhRMA Back Call For Fed. Circ. To Broaden AIA Estoppel
Two major drug industry groups urged the Federal Circuit Thursday to expand the reach of the America Invents Act inter partes review estoppel provision, arguing that lower courts have read it too narrowly and are wrongly allowing patent challengers to relitigate invalidity arguments in court.
-
January 27, 2017
Illumina Urges Fed. Circ. To Broaden Reach Of AIA Estoppel
Illumina Inc. asked the Federal Circuit Friday to clarify which invalidity arguments the inter partes review estoppel provision bars petitioners from raising in litigation after a patent is reviewed, saying district judges have made "clear and indisputable" errors in allowing too many arguments.